BioCryst Pharmaceuticals' Q3 Net Income, Revenue Rise; Increases 2026 Revenue Guidance

09:23 AM EST, 11/04/2026 (MT Newswires) -- BioCryst Pharmaceuticals (BCRX) reported Q3 net income Wednesday of $0.14 per diluted share, compared with $0.06 a year earlier. Analysts surveyed by FactSet expected $0.09. Revenue for the quarter ended Sept. 30 was $180.3 million, compared with $159.4 million a year earlier. Analysts surveyed by FactSet expected $165.7 million. For 2026, the company raised its revenue guidance to a range of $715 million to $730 million from its previous outlook of $690 million to $715 million. Analysts surveyed by FactSet expect $710.1 million.